d8k.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
 

 
FORM 8-K
 
 
 

 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
February 2, 2011
Date of Report (date of earliest event reported)
 
 

 
Cutera, Inc.
(Exact name of Registrant as specified in its charter)
 
 

 
         
Delaware
 
000-50644
 
77-0492262
(State or other jurisdiction of
incorporation or organization)
 
(Commission File Number)
 
(I.R.S. Employer
Identification Number)
 
3240 Bayshore Blvd.
Brisbane, California 94005
(Address of principal executive offices)
 
(415) 657-5500
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
Item 2.02.
Results of Operations and Financial Condition.
 
On February 2, 2011, we are issuing a press release and holding a conference call regarding our financial results for the fourth quarter ended December 31, 2010. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
 
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01.
Financial Statements and Exhibits.
 
(d)
Exhibits.
 
     
 
Exhibit No.
 
  
Description
   
99.1
  
Press Release of Cutera, Inc. dated as of February 2, 2011.

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
         
       
CUTERA, INC.
     
Date: February 2, 2011
     
 /s/ RONALD J. SANTILLI
       
Ronald J. Santilli
       
EVP, Finance and Administration and Chief Financial Officer

dex991.htm
 

FOR IMMEDIATE RELEASE

CONTACTS:

Cutera, Inc.
Ron Santilli
Chief Financial Officer
415-657-5500

Investor Relations
John Mills
Integrated Corporate Relations, Inc.
310-954-1100
john.mills@icrinc.com

Cutera Reports Fourth Quarter 2010 Results

BRISBANE, Calif., February 2, 2011 -- Cutera, Inc. (NASDAQ: CUTR), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the fourth quarter ended December 31, 2010.

Fourth quarter 2010 revenue was $15.2 million, compared to $15.4 million in the same period last year.  Net loss for the fourth quarter of 2010 was $1.3 million, or $0.09 per diluted share.

Kevin Connors, President and CEO of Cutera, stated, “Our fourth quarter and annual 2010 revenue remained flat, compared to the same periods in 2009. During the fourth quarter of 2010, US revenue increased by 9%, compared to the fourth quarter of 2009, due primarily to the sales productivity initiatives recently implemented and the launch of our Genesis Plus product. Although our international revenue declined by 7% during the fourth quarter of 2010, compared to the fourth quarter of 2009, we generated record revenue in Japan as a result of the strong performance of all products, including our recently added Filler and Cosmeceutical products.”
 
“We are encouraged with the significant progress made to date on our new product development efforts.  In the fourth quarter of 2010, we continued our launch of our Genesis Plus product and we are pleased with the initial market response.  This is a standalone product for the treatment of toenail fungus (CE mark approved and FDA clearance pending) as well as a rejuvenation application. We are on target to introduce at the American Academy of Dermatology meeting this weekend our “top of class” vascular laser- Excel V-  which already has an FDA clearance for broad vascular applications.  In addition, we plan to release an additional new product in the second half of 2011.”

“We are excited about Len DeBenedictis joining our management team as Chief Technical Officer and believe he will bring an increased focus to the critical role of leading our research and product development efforts. Further, we are pleased with the strengthening of our sales management team through the addition of Michael Poole as Vice President of North American Sales, who will focus on this historically significant geographical market. This management change will allow Chris West to dedicate his time to further develop our Japan and Asia Pacific markets. We believe these strategic changes significantly strengthen our executive management team and position us for growth in 2011 and beyond.”

Mr. Connors concluded, “We remain focused on key initiatives to increase future revenue levels and leverage our business model, which we expect will result in improved performance and cash generation in 2011.  As the near-term prospects for our industry have stabilized,  we believe that our worldwide distribution network, strong balance sheet with approximately $97 million in cash and investments – with no debt – a broad portfolio of products, and various research and development projects underway, offer continuing, long-term opportunities for our company.”

Conference Call:

The conference call to discuss these results is scheduled to begin at 2:00 p.m. PT (5:00 p.m. ET) on February 2, 2011. The call will be broadcast live over the Internet hosted at the Investor Relations section of Cutera's website at www.cutera.com, and will be archived online within one hour of its completion through 8:59 p.m. PT (11:59 p.m. ET) on February 16, 2011. In addition, you may call (877) 407-0784 to listen to the live broadcast. Participating in the call will be Kevin Connors, President and Chief Executive Officer, and Ron Santilli, Executive Vice President and Chief Financial Officer.
 
 
About Cutera, Inc.
 
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
 
 
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning Cutera's ability to leverage its business model, increase revenue, generate additional cash, increase profitability, realize benefits from changes in management, develop and commercialize existing and new products and applications, and statements regarding long-term prospects and opportunities are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein.  Potential risks and uncertainties that could affect Cutera's business and cause its financial results to differ materially from those contained in the forward-looking statements include the current economic uncertainty, which may reduce consumer demand for its products, cause potential customers to delay their purchase decisions and make it more difficult for some potential customers to obtain credit financing; its ability to increase revenue, manage costs and expenses and improve sales productivity and  performance worldwide; its ability to successfully develop and acquire new products and applications and market them to both its installed base and new customers; the length of the sales cycle process; unforeseen events and circumstances relating to its operations; government regulatory actions; and those other factors described in the section entitled, “Risk Factors,” in its most recent Form 10-Q as filed with the Securities and Exchange Commission on November 1, 2010. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligati on to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. Cutera's fourth quarter ended December 31, 2010 financial performance, as discussed in this release, is preliminary and unaudited, and subject to adjustment.
 
 
 
 
 

 
 
CUTERA, INC.
 
CONDENSED CONSOLIDATED BALANCE SHEETS
 
(in thousands)
 
(unaudited)
 
   
   
December 31,
   
September 30,
   
December 31,
 
   
2010
   
2010
   
2009
 
Assets
                 
Current assets:
                 
Cash and cash equivalents
  $ 12,519     $ 21,703     $ 22,829  
Marketable investments
    77,484       69,154       76,780  
Accounts receivable, net
    4,208       3,024       3,327  
Inventories
    6,448       7,144       6,408  
Deferred tax asset
    63       204       175  
Other current assets and prepaid expenses
    2,740       2,855       2,785  
Total current assets
    103,462       104,084       112,304  
                         
Property and equipment, net
    597       624       847  
Long-term investments
    6,784       6,683       7,275  
Intangibles, net
    637       685       829  
 Deferred tax asset, net of current portion     325        97        97   
Total assets
  $ 111,805     $ 112,173     $ 121,352  
                         
   Liabilities and Stockholders' Equity
                       
Current liabilities:
                       
Accounts payable
  $ 1,296     $ 1,701     $ 1,081  
Accrued liabilities
    6,194       5,821       9,048  
Deferred revenue
    5,633       5,757       6,160  
Total current liabilities
    13,123       13,279       16,289  
                         
Deferred rent
    1,501       1,504       1,493  
Deferred revenue, net of current portion
    1,287       1,302       1,968  
Income tax liability
    477       566       749  
Total liabilities
    16,388       16,651       20,499  
                         
Stockholders’ equity:
                       
Common stock
    14       14       13  
Additional paid-in capital
    90,423       89,296       85,248  
Retained earnings
    6,736       8,016       17,254  
Accumulated other comprehensive loss
    (1,756 )     (1,804 )     (1,662 )
Total stockholders' equity
    95,417       95,522       100,853  
Total liabilities and stockholders' equity
  $ 111,805     $ 112,173     $ 121,352  
                         
 
 
 
 
 

 
 
 
CUTERA, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 
(in thousands, except per share data)
 
(unaudited)
 
   
 
Three Months Ended
 
 
December 31,
   
September 30,
   
December 31,
 
 
2010
   
2010
   
2009
 
Net revenue
  $ 15,216     $ 12,092     $ 15,416  
Cost of revenue
    6,233       5,661       5,783  
Gross profit
    8,983       6,431       9,633  
                         
Operating expenses:
                       
Sales and marketing
    6,123       5,799       6,100  
Research and development
    2,173       1,871       1,888  
General and administrative
    2,238       2,352       2,063  
Total operating expenses
    10,534       10,022       10,051  
Loss from operations
    (1,551 )     (3,591 )     (418 )
Interest and other income, net
    144       132       174  
Loss before income taxes
    (1,407 )     (3,459 )     (244 )
Benefit for income taxes
    (127 )     -       (251 )
Net income (loss)
  $ (1,280 )   $ (3,459 )   $ 7  
                         
Net income (loss) per share:
                       
Basic and Diluted
  $ (0.09 )   $ (0.25 )   $ -  
                         
Weighted-average number of shares used in per share calculations:
                       
Basic
    13,622       13,589       13,427  
Diluted
    13,622       13,589       13,610  
 
 
 
 

 
CUTERA, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 
(in thousands)
 
(unaudited)
 
   
   
Three Months Ended
 
   
December 31,
   
September 30,
   
December 31,
 
   
2010
   
2010
   
2009
 
Cash flows from operating activities:
                 
Net income (loss)
  $ (1,280 )   $ (3,459 )   $ 7  
Adjustments to reconcile net income (loss) to net cash provided by
                       
 (used in) operating activities:
                       
Stock-based compensation
    980       1,081       840  
Tax benefit from stock-based compensation
    8       -       111  
Excess tax deficit related to stock-based compensation
    (8 )     -       (23 )
Depreciation and amortization
    157       167       196  
Provision for excess and obsolete inventories
    18       131       364  
Provision for doubtful accounts receivable
    (31 )     (7 )     (25 )
Gain on sale of marketable investments, net
    -       (8 )     -  
Change in deferred tax asset
    (87 )     (19 )     (28 )
Changes in assets and liabilities:
                       
Accounts receivable
    (1,153 )     807       (667 )
Inventories
    678       (320 )     1,112  
Other current assets and prepaid expenses
    553       688       339  
Accounts payable
    (405 )     206       (131 )
Accrued liabilities
    412       148       1,728  
Deferred rent
    (42 )     (48 )     (16 )
Deferred revenue
    (139 )     (212 )     (498 )
Income tax liability
    (89 )     (166 )     (133 )
Net cash provided by (used in) operating activities
    (428 )     (1,011 )     3,176  
                         
Cash flows from investing activities:
                       
Acquisition of property and equipment
    (82 )     (35 )     (56 )
Proceeds from sales of marketable and long-term investments
    4,030       9,099       7,120  
Proceeds from maturities of marketable investments
    8,370       14,810       975  
Purchase of marketable investments
    (21,220 )     (32,884 )     (22,860 )
Net cash used in investing activities
    (8,902 )     (9,010 )     (14,821 )
                         
Cash flows from financing activities:
                       
Proceeds from exercise of stock options and employee stock purchase plan
    138       27       149  
Excess tax benefit related to stock-based compensation
    8       -       23  
Net cash provided by financing activities
    146       27       172  
                         
Net decrease in cash and cash equivalents
    (9,184 )     (9,994 )     (11,473 )
Cash and cash equivalents at beginning of period
    21,703       31,697       34,302  
Cash and cash equivalents at end of period
  $ 12,519     $ 21,703     $ 22,829  

 
 

 
 
CUTERA, INC. 
CONSOLIDATED REVENUE HIGHLIGHTS 
(in thousands, except percentage data) 
(unaudited) 
 
   Three Months Ended  
 
    Three Months Ended           Three Months Ended      
 
December 31,
 
% of
   
September 30,
 
% of
   
December 31,
 
% of
 
  2010   
Revenue
    2010   
Revenue
    2009   
Revenue
 
Revenue By Geography:
                           
United States
$ 5,793   38 %   $ 4,214   35 %   $ 5,298   34 %
International
  9,423   62 %     7,878   65 %     10,118   66 %
  $ 15,216         $ 12,092         $ 15,416      
                                   
Revenue By Product Category:
                                 
Products (1)
$ 8,920   58 %   $ 5,767   48 %   $ 8,083   52 %
Upgrades
  869   6 %     1,414   12 %     2,036   13 %
Service
  3,314   22 %     3,166   26 %     3,327   22 %
Titan hand piece refills
  934   6 %     647   5 %     1,524   10 %
Dermal fillers and cosmeceuticals (1)
  1,179   8 %     1,098   9 %     446   3 %
  $ 15,216         $ 12,092         $ 15,416      
                                   
(1) Beginning in 2010, we classified revenue from dermal fillers and cosmeceuticals product in the revenue category ‘Dermal fillers and cosmeceuticals.’ Previously, we classified these sales in the revenue category ‘Products.’ As such, we reclassified the 2009 revenue from ‘Products’ to ‘Dermal fillers and cosmeceuticals.’